PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer

Phase III study finds perioperative nivolumab plus chemotherapy significantly lowers chance of disease recurrence, progression or death compared to chemotherapy alone

ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
2023-10-21
(Press-News.org) MADRID ― Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer (NSCLC). Results from the Phase III CheckMate 77T study were presented today at the 2023 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

At a median follow-up of 25.4 months, the median EFS with chemotherapy alone was 18.4 months, while the median had not yet been reached for patients receiving perioperative nivolumab, meaning EFS was prolonged significantly over the control group. These results correspond to a 42% reduction in risk of disease progression, recurrence, or death for those receiving the perioperative combination.

Patients who received the perioperative nivolumab-based regimen also saw significantly higher rates of pathological complete response (pCR), defined as no tumor remaining at surgery, compared with those who received chemotherapy alone (25.3% vs. 4.7%). Rates of major pathological response (MPR), less than or equal to 10% of viable tumor cells remaining at time of surgery, were also higher in patients who received perioperative immunotherapy (35.4% vs. 12.1%).

“This study builds on the standard-of-care neoadjuvant treatment and supports perioperative nivolumab as an effective approach that reduces the risk of lung cancer relapse,” said principal investigator Tina Cascone, M.D., Ph.D., associate professor of Thoracic/Head & Neck Medical Oncology. “These findings add to evidence that the perioperative immunotherapy path gives patients with operable lung cancer an opportunity to live longer without their cancer returning.” 

Roughly 30% of patients diagnosed with NSCLC have operable disease, meaning their tumor can be removed by a surgical operation. While many of these patients can be potentially cured by surgery, more than half will experience cancer recurrence without additional therapy. Chemotherapy given either before or after surgery provides only a minimal survival benefit.

The randomized, double-blind CheckMate 77T trial, which began in 2019, included more than 450 NSCLC patients over the age of 18 from around the globe. Participants were randomized to treatment with either neoadjuvant nivolumab with chemotherapy followed by surgery and adjuvant nivolumab, or neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo

The data showed no new safety signals with the perioperative nivolumab regimen and is consistent with the known safety profiles of individual agents. Grade 3-4 treatment-related side effects were observed in 32% and 25% of patients receiving the perioperative combination or control therapy, respectively. Surgery-related adverse events occurred in 12% of patients in both treatment arms.

These findings add to recent success seen with neoadjuvant nivolumab plus chemotherapy in NSCLC. In March 2022, the Phase III CheckMate 816 study led to FDA approval of nivolumab combined with platinum-based chemotherapy.

“I am enthusiastic about the initial findings of the study,” Cascone said. “Looking ahead, it will be critical to identify patient and disease characteristics that will tell us who can potentially be cured with neoadjuvant immunotherapy only and who will benefit from more intensified treatment strategies.”

The CheckMate 77T study was sponsored by Bristol Myers Squibb. A full list of co-authors and author disclosures can be found here.

Read this press release on the MD Anderson Newsroom.

END

[Attachments] See images for this press release:
ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer

ELSE PRESS RELEASES FROM THIS DATE:

Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus

2023-10-21
Boston – Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial. The trial, led by Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Cancer at Dana-Farber Cancer Institute, showed the risk of progression was reduced by 25-26%. The results were presented at the annual European Society for Medical Oncology (ESMO) Congress on October ...

THE LANCET JOURNALS: Papers publishing during the European Society for Medical Oncology Congress 2023 (#ESMO 2023), 20th – 24th October 2023

2023-10-21
The following Lancet papers will be presented at the European Society for Medical Oncology Congress 2023 (#ESMO 2023). The conference will take place between Friday 20th – Tuesday 24th October 2023.  Contact details for corresponding authors are provided should you wish to arrange an interview with the authors. Funding information is listed on the first page of each Article. **Embargo: 13.00 [BST] / 14.00 [CEST] Friday 20th October 2023** The Lancet: Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase ...

Highest risk patients with clear-cell renal cell carcinoma benefit from adjuvant everolimus

2023-10-21
A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery. The results will be presented at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on Oct. 23, 2023 (poster 1887P) by Primo N. Lara, Jr., MD, lead author on the abstract. ...

American Academy of Pediatrics sounds the alarm on excessive noise and risks to children’s hearing in updated policy statement

2023-10-21
  Media contacts: Lisa Black, lblack@aap.org; or Adam Alexander, aalexander@aap.org     The parent’s universal cry in response to loud music-- “Turn that thing down!” -- is well-founded, as evidence shows that children and teens risk hearing loss by cranking up their personal listening devices. What families may not realize is that children are exposed to potentially harmful noise from infancy and that the effects are cumulative over a lifetime.   The American Academy of Pediatrics discusses the common sources and effects of noise, from infant sleep ...

Bioengineering team wins health care innovation competition

Bioengineering team wins health care innovation competition
2023-10-20
Four senior bioengineering students at The University of Texas at Arlington have won the Biomedical Engineering Society (BMES) Coulter College for Healthcare Innovation competition for their work on an early detection device for atrial fibrillation. Brady Killham, Juan Ramirez, Jeannette Santos and Michael Ikefuna, all seniors in UTA’s Bioengineering Department, earned the Best Overall award for their plan to develop FibGuard, a wearable, non-invasive atrial fibrillation early detection device. UTA competed against teams from Vanderbilt, Purdue, Virginia Tech, Wake Forest, Texas A&M, the University of Oklahoma and Rensselaer Polytechnic ...

Antimicrobial peptides modulate lung injury by altering the intestinal microbiota

Antimicrobial peptides modulate lung injury by altering the intestinal microbiota
2023-10-20
BIRMINGHAM, Ala. – Lung development in the fetus occurs at low oxygen tension in the womb, but after a very premature birth, the partly developed lungs of the tiny infants experience far greater oxygen tensions even without the prolonged supplemental oxygen that is often required. This can produce well-known disastrous effects on the structure and function of the neonatal lung, causing the serious lung condition of bronchopulmonary dysplasia in high-risk premature infants. Using a neonatal mouse model, researchers ...

Diagnosis and management of postoperative wound infections in the head and neck region

Diagnosis and management of postoperative wound infections in the head and neck region
2023-10-20
“The majority of wound infections often manifest themselves immediately postoperatively, so close followup should take place [...]” BUFFALO, NY- October 20, 2023 – A new research perspective was published in Oncoscience (Volume 10) on October 4, 2023, entitled, “Diagnosis and management of postoperative wound infections in the head and neck region.” In everyday clinical practice at a department for oral and maxillofacial surgery, a large number of surgical procedures in the head and neck region take place under both outpatient and inpatient conditions. The basis ...

Brain & Behavior Research Foundation awards $10.2 million in Young Investigator Grants to 150 mental health scientists

2023-10-20
The Brain & Behavior Research Foundation announced it is awarding $10.2 million in Young Investigator Grants to 150 promising early career scientists who are working to identify causes, improve treatments, and develop methods of prevention for psychiatric illnesses that impact millions of people in the United States and around the world. The 2023 Young Investigators are focused on a broad range of psychiatric illnesses. More than half of the projects are relevant to the study or treatment of depression and schizophrenia. Addiction/substance-use disorders, anxiety, and ...

Contaminants in cannabis and hemp flowers create potential for health risks

Contaminants in cannabis and hemp flowers create potential for health risks
2023-10-20
Cannabis use, even for medical purposes, could make some people sick due to harmful fungi that contaminate the plants. That is the finding of a recently published peer-reviewed journal article, whose authors recommend further study and consideration of changes to regulations to protect consumers, especially those who are immunocompromised. They examined data, previous studies, and U.S. and international regulations related to the cannabis and hemp industry. The article was published in Frontiers in Microbiology. It was researched and written by Kimberly Gwinn, professor of entomology and plant pathology at the University of Tennessee Institute ...

COVID-19-related jail decarceration did not affect crime in California

2023-10-20
Since 2011, California has significantly reformed its criminal justice system, reducing the size of its prison population, with no effect on violent crime and only marginal impacts on property crime statewide. The COVID-19 pandemic furthered decarceration as the state reduced state prison and jail populations to slow the spread of the virus. Concerns emerged that releases under the auspices of COVID mitigation harmed public safety. A new study explored this notion and found no consistent relation between COVID-19-related jail decarceration and violent or property ...

LAST 30 PRESS RELEASES:

New initiative launched to improve care for people with certain types of heart failure

You’ve never seen corn like this before

Mediterranean diet could reduce gum disease

Mount Sinai launches cardiac catheterization artificial intelligence research lab

Why AI is never going to run the world

Stress in the strands: Hair offers clues to children’s mental health

UCLA distinguished professor, CVD researcher to receive 2025 Basic Research Prize

UT San Antonio School of Public Health: The People’s School

‘Preventable deaths will continue’ without action to make NHS more accessible for autistic people, say experts

Scientists shoot lasers into brain cells to uncover how illusions work

Your ecosystem engineer was a dinosaur

New digital cognitive test for diagnosing Alzheimer's disease

Parents of children with health conditions less confident about a positive school year

New guideline standardizes consent for research participants in Canada

Research as reconciliation: Oil sands and health

AI risks overwriting history and the skills of historians have never been more important, leading academic outlines in new paper

The Lancet Diabetes & Endocrinology: Higher doses of semaglutide can safely enhance weight loss and improve health for adults living with obesity, two new clinical trials confirm

Trauma focused therapy shows promise for children struggling with PTSD

School meals could drive economic growth and food system transformation

Home training for cerebellar ataxias

Dry eyes affect over half the general population, yet only a fifth receive diagnosis and treatment

Researchers sound warning about women with type 2 diabetes taking oral HRT

Overweight and obesity don’t always increase the risk of an early death, Danish study finds

Cannabis use associated with a quadrupling of risk of developing type 2 diabetes, finds study of over 4 million adults

Gestational diabetes linked to cognitive decline in mothers and increased risk of developmental delays, ADHD and autism among children

Could we use eye drops instead of reading glasses as we age?

Patients who had cataracts removed or their eyesight corrected with a new type of lens have good vision over all distances without spectacles

AI can spot which patients need treatment to prevent vision loss in young adults

Half of people stop taking popular weight-loss drug within a year, national study finds

Links between diabetes and depression are similar across Europe, study of over-50s in 18 countries finds

[Press-News.org] ESMO: Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer
Phase III study finds perioperative nivolumab plus chemotherapy significantly lowers chance of disease recurrence, progression or death compared to chemotherapy alone